Abstract: The present invention relates to skin care compositions comprising one or more inorganic particulate materials selected from the group consisting of delaminated talc, delaminated bentonite, an alkaline earth metal carbonate or sulphate, such as calcium carbonate, magnesium carbonate, dolomite, gypsum, a hydrous kandite clay such as delaminated kaolin, halloysite or ball clay, an anhydrous or calcined kandite clay such as metakaolin or fully calcined kaolin, mica, perlite or diatomaceous earth, or magnesium hydroxide, or aluminium trihydrate, or combinations thereof; and/for wherein the inorganic particulate material has a BET surface area of least about 10.0 m2/g. The present invention further extends to the use of such compositions.

Abstract: A subject matter of the present invention is a composition comprising: a) at least multilayer spherical composite particles comprising i) a core comprising at least one material A having a refractive index ranging from 1.3 to 1.8; and ii) at least one layer covering said core, comprising at least one material B having a refractive index ranging from 1.9 to 3.1; and iii) optionally at least one second layer covering the material B, comprising at least one material C having a refractive index ranging from 1.3 to 1.8; said composite particles being present in an amount less than 28.0% by weight relative to the total weight of the composition; and b) at least one UV-screening agent. This composition is for topical use and is more particularly intended for the photoprotection of the skin and/or hair against ultraviolet (UV) radiation.

Abstract: A porous silica particle with the small specific surface area and large pore volume, which is contained as the scrubbing agent in the cleansing cosmetics is provided. The porous silica particle has high collapsibility, and therefore the damage of the skin can be prevented. A porous silica particle according to the present invention has: an average circularity of 0.1 to 0.5; a pore volume of 0.1?Pv<1.0 ml/g; a specific surface area of 5 to 60 m2/cm3; a median size of 100 to 1000 ?m; a ratio of a maximum particle diameter to the median size, of 3.0 or less; and a median size of 5 to 40 ?m and a maximum particle diameter of 15 to 200 ?m, after rubbing for 30 seconds with a load of 1.0 to 1.4 KPa.

Abstract: A composition and method is provided for synthesizing silicone particles with narrow size distributions and tunable degrees of crosslinking for encapsulation of an active ingredient or multiple active ingredients in the matrix of the particles for controlled release. The method comprises agitating at least one type of silane monomer having two, three or four siloxane bonds in an acidic aqueous solution under conditions sufficient to allow for hydrolysis of the monomers, adding a catalyst and a solution comprising a co-solvent and the active ingredient(s) to the acidic aqueous solution, and continuing to agitate the combined solution to allow for a condensation reaction and formation of silicone particles with a narrow size distribution encapsulating at least a portion of the active ingredient(s). The tunable degree of crosslink density of the particles formed is based on the ratios of the monomers used, which enables controlled release of the active ingredient(s) from the particles.

Abstract: An encapsulated perfume composition wherein the shell contains a polyurea resin and the core contains a perfume comprising an aldehyde-containing perfume ingredient or ingredients, a non-aromatic cyclic perfume ingredient, and an alkyl salicylate and/or a 2,2,2-trisubstituted acetal,

Abstract: The present disclosure relates to methods, compositions and apparatus for monitoring and improving oral health by utilizing information about nitric oxide levels in an individual's oral cavity. In an embodiment, the disclosure provides methods and apparatus for monitoring nitric oxide metabolites in saliva; this information may be utilized as it relates to improving oral health, i.e. monitoring and improving oral hygiene and increasing the consumption of nitric oxide-potent foods. In an embodiment, methods for improving oral health in a subject comprising, use of an oral cleanser by an individual, wherein the oral cleanser comprises a potassium nitrate source; and use of a saliva test strip for measuring nitrite and nitrogen oxides in the oral cavity of the individual are provided. In an embodiment, a novel nitrate-rich gum composition is provided.

Abstract: The present invention relates to carriers for the controlled release of active agents, comprising surface reacted natural or synthetic calcium carbonate, one or more active agents, wherein said one or more active agent is associated with said surface-reacted calcium carbonate, and wherein said surface-reacted natural or synthetic calcium carbonate is a reaction product of natural or synthetic calcium carbonate with carbon dioxide and one or more acids, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source. It further relates to the preparation of loaded carriers, as well as their use in different applications.

Abstract: The invention provides a hair shaping composition suitable for topical application to hair, the composition comprising from 1 to 25 wt % of one or more C2-4 monoaldehydes and from 1 to 25 wt % of one or more urea compounds; dissolved or dispersed in an aqueous carrier.

Abstract: An object of the present invention is to provide an external composition for skin excellent in ultraviolet-ray absorbability. The present invention relates to the external composition for skin comprising (a) an ultraviolet-ray absorber, and (b) an inorganic phosphor. (a) The ultraviolet-ray absorber preferably contains at least one ultraviolet-ray absorber which absorbs UVB. Also, (a) the ultraviolet-ray absorber is more preferably at least one ultraviolet-ray absorber selected from the group consisting of 2-ethylhexyl paramethoxycinnamate, phenylbenzimidazole sulfonic acid, etc.

Abstract: The present invention relates to the use of phenyl ketone derivatives of the formula I for use as self-tanning substance or for increasing melanin synthesis, improving melanin transport and/or improving the distribution of melanin in suprabasal layers, and to preparations comprising these phenyl ketone derivatives.

Abstract: The present invention relates to the cosmetic use of topical compositions comprising 10-hydroxystearic acid, a salt or ester thereof, for application to human skin for improving the condition and appearance of skin more particularly as an anti-wrinkle, for promoting a homogenous skin tone, for reduction of skin pore size, as a photo-protecting agent, and/or for improvement of the skin barrier function.

Abstract: A personal care composition including at least one dry emollient and one oily emollient, where the personal care composition is free of silicone or silicone containing materials.

Abstract: The present invention relates to an oil-in-water emulsion with globules of oil, the number-average size of which is less than or equal to 200.0 nm, comprising: a) a continuous aqueous phase, b) an oily phase dispersed in said aqueous phase, c) a mixture of nonionic surfactants comprising: (i) at least one alkoxylated fatty ester, and (ii) at least one fatty ester of glycerol, d) at least one anionic amphiphilic lipid, e) at least one liposoluble organic UV-screening agent, characterized in that it does not comprise any monoalcohol comprising from 2 to 8 carbon atoms, and that the weight ratio of the amount of oily phase to the total amount of nonionic surfactants and anionic amphiphilic lipid is from 2 to 20. The invention also relates to a cosmetic process for limiting the darkening of the skin and/or improving the colour and/or uniformity of the complexion, comprising the application, to the surface of the keratin material, of a composition as defined previously.

Abstract: The present invention is directed to a personal care composition comprising from about 14% to about 40% of one or more surfactants; from about 0.1% to about 10% of one or more surfactant soluble agents having a C log P greater than 3.0; wherein when the personal care composition is diluted to about 1.5% surfactant concentration has a ratio of surfactant diffusion coefficient to soluble agent diffusion coefficient greater than 1.2.

Abstract: The present disclosure relates to gentle cleansing compositions, which generally include: (a) a taurate surfactant; (b) an isethionate surfactant; (c) a betaine (and/or another amphoteric surfactant); and (d) a nonionic emulsifier. The cleansing compositions exhibit very good cleansing properties, are particularly effective for removing makeup, and are mild and moisturizing to the skin.

Abstract: Compositions including a discontinuous oil phase homogeneously dispersed in a continuous water phase, the oil phase including a sunscreen agent that includes a linear, ultraviolet radiation absorbing polyether that comprises a chemically bound UV-chromophore; and an oil-in water emulsifier component including an anionic oil-in-water emulsifier and a nonionic oil-in-water emulsifier having an alcohol functional group, wherein the weight ratio of the anionic oil-in-water emulsifier to the nonionic oil-in-water emulsifier is about 12 or less and wherein the linear, ultraviolet radiation absorbing polyether is present in an amount effective to provide the composition with an SPF of about 10 or greater.

Abstract: The present disclosure discloses a novel use of genistein, epigallocatechin gallate (EGCG), derivatives thereof, isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates thereof and solvates thereof. A composition containing genistein, epigallocatechin gallate, derivatives thereof isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates thereof or solvates thereof reduces the expression of factors related to increase of melanin producing ability, reduces the expression of senescence marker proteins and regulates the expression of enzymes involved in melanin production, and thus may have an effect of rejuvenating cells including melanocytes.

Abstract: The present disclosure is directed to stabilizing compositions comprising a mixture of three or more ultraviolet filters. The disclosed compositions are useful for stabilizing the color and the fragrance of formulations, including cosmetic formulations and household products.

Abstract: A compound of formula (I) is disclosed, in which R? and R?, which may be identical or different, represent either a hydrogen atom or a monovalent radical of formula (IIa); or of a composition (C1) including between 99% and 20% by mass of a compound of formula (Ia), and between 1% and 80% by mass of a compound of formula (1b), with the aim of preventing or retarding the appearance of the signs of ageing of the human skin or lips or to eliminate the signs, the use being in the form of a cosmetic composition. Also disclosed is a method using the product of formula (I) or composition (C1).

Abstract: Provided are methods of diminishing the signs of aging and/or improving the health of human integuments, such as skin, and compositions comprising peptides useful therefor. The compositions according to the invention comprise a peptide comprising the sequence selected from LRLK (SEQ ID NO: 1), MVV (SEQ ID NO: 2), TAKDGAP (SEQ ID NO: 3), IFGGTVYRS (SEQ ID NO: 4), and RTPKISKPIKFELSG (SEQ ID NO: 5) or a derivative, or fragment thereof, in a topically acceptable vehicle.

Abstract: The present invention relates to a cosmetic composition comprising a dispersion of acrylic polymer particles, a semi-crystalline polymer and an organic solvent. The compositions of the present invention may optionally contain at least one colorant. The invention also relates to a method for making up and/or enhancing the appearance of a keratinous substrate, in particular lashes, by applying these compositions to the keratinous substrate.

Abstract: The present invention relates to a cosmetic composition comprising a thermoplastic elastomer, a semi-crystalline polymer and an organic solvent. The compositions of the present invention may optionally contain at least one colorant. The invention also relates to a method for making up and/or enhancing the appearance of a keratinous substrate, in particular lashes, by applying these compositions to the keratinous substrate.

Abstract: The present invention relates to a cosmetic composition comprising a dispersion of acrylic polymer particles, a thermoplastic elastomer, a semi-crystalline polymer and an organic solvent. The compositions of the present invention may optionally contain at least one colorant. The invention also relates to a method for making up and/or enhancing the appearance of a keratinous substrate, in particular lashes, by applying these compositions to the keratinous substrate.

Abstract: A hair conditioning composition comprising: a) at least one cationic surfactant compound; b) at least one fatty acid ester of an ethoxylated alkyl glucoside; c) at least one nonionic, amphiphilic, emulsion polymer; d) an aqueous carrier; and optionally, e) at least one other auxiliary conditioning agent different than (a) said other conditioning agent is selected from a silicone, a hydrocarbon oil, a natural oil, an ester oil, a cationic compound, a cationic polymer, and combinations thereof.

Abstract: The present invention relates to a composition in the form of an emulsion containing portions of hollow spheres of organosilicon-based material, the portions of hollow spheres having a mean diameter ranging from 0.05 to 10 ?m. The invention also relates to physiologically acceptable emulsion compositions comprising hollow spheres, and to a process for fading out skin surface defects, in particular to reduce the sheen of the skin and/or to fade out pores, shadows under the eyes, marks, wrinkles and/or fine lines, comprising the topical application to the skin of the above-mentioned compositions.

Abstract: A method of treating the hair including providing a concentrated hair care composition in a foam dispenser. The concentrated hair care composition includes one or more silicones, perfume, and less than 6% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm3 to about 0.40 g/cm3 when dispensed from the foam dispenser. The one or more silicones form a silicone layer that has a normalized thickness of deposition of from about 0.001 nm/ppm to about 0.019 nm/ppm.

Abstract: A method of treating the hair including providing a concentrated hair care composition in a foam dispenser. The concentrated hair care composition includes one or more silicones, perfume, and less than 6% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm3 to about 0.40 g/cm3 when dispensed from the foam dispenser. The one or more silicones form a silicone layer that has a Targeted Deposition Index of from about 0.8 to about 1.6.

Abstract: A method of treating the hair including providing a concentrated hair care composition in a foam dispenser. The concentrated hair care composition includes one or more silicones, perfume, and less than 6% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm3 to about 0.40 g/cm3 when dispensed from the foam dispenser. The one or more silicones form a silicone layer that has a Hair Damage Repair Index of from about 0.8 to about 4.0.

Abstract: Compositions comprising emu oil as a vehicle for the delivery of other active ingredients for the treatment of cosmetic and other skin imperfections such as acne, wrinkles, and hair loss are disclosed. Methods of treating cosmetic and other skin imperfections using the compositions are also disclosed.

Abstract: Oriental medicinal collagen food and manufacturing method of the oriental medicinal collagen food for skin beauty enhancement are provided. The manufacturing method including: a first process including: removing claws and scales from chicken feet, and preparing dandelion, angelica gigas, and pueraria root; a second process including: performing high-pressure pasteurization for the chicken feet obtained in the first process; a third process including: preparing dandelion extract by heating the dandelion in a bag; a fourth process including: obtaining Gyepogyo by heating and fermenting the pasteurized chicken feet and the dandelion extract in a pot; and a fifth process including: obtaining extract and distillate from a distillation of a mixture comprising the Gyepogyo, the angelica gigas, and the pueraria root.

Abstract: The present invention relates to a method for protecting the skin against UV rays, using at least two cosmetic skincare and/or make-up compositions, comprising: the application, to at least part of the skin of the body or face, of at least a first layer of a first cosmetic composition comprising an oil phase and, optionally, an aqueous phase, followed by the application, on said first layer, of at least a second layer of a second anhydrous composition comprising at least 70 wt.-% powders selected from among fillers and pigments, and an oil phase, said method being characterized in that at least one of the two compositions contains at least one UV filter, preferably a liposoluble UV filter. The liposoluble UV filter is preferably in the second composition. The first composition is a make-up foundation or skincare base. The second composition is advantageously a loose or compact powder.

Abstract: Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.

Abstract: A formulation for generating an adhesion barrier that includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable polymer and at least one water soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The formulation of particles is deposited on a surface of internal body tissue and the deposited formulation absorbs moisture from the tissue and forms a film over the surface. The film acts as an adhesion barrier by reducing or preventing adhesion of the surface to other body tissue.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: A non-irritation, non-blurring, photostable ophthalmic sunscreen composition contains at least one of the following: bemotrizinol; bisoctrizole; tris-biphenyl triazine; and/or octyl methoxycinnamate. A liquid vehicle base is then a remainder of the solution by weight. The composition is an artificial tear formulation or an ophthalmic suspension or ointment. The composition may include at least one inorganic and/or at least one organic active ingredient. The inorganic active ingredients may include, but not be limited to zinc oxide, titanium dioxide, iron oxide, zirconium oxide, and cerium oxide. The organic active ingredients may include, but not be limited to dioxybenzone, octinoxate, octisalate, homosalate, avobenzone, octocrylene, para-aminobenzoic acid, cinoxate, methyl anthranilate, octocrylene, padimate O, ensulizole, sulisobenzone, trolamine salicylate, and ecamsule.

Abstract: A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.

Abstract: The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide or protein drugs with advantageously high bioavailability, safety and cost-effectiveness. In particular, the invention provides a peptide or protein drug having a molecular weight of equal to or less than about 50 kDa for use as a medicament, wherein said peptide or protein drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex, and with a pharmaceutically acceptable reducing agent. The invention also provides a pharmaceutical composition comprising: a peptide or protein drug having a molecular weight of equal to or less than about 50 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex; and a pharmaceutically acceptable reducing agent.

Abstract: An orally disintegrating tablet including: fine granules, each fine granule having, at its center, an active pharmaceutical ingredient-containing core that includes butylscopolamine bromide and water-insoluble particles, and having an intermediate layer that includes water-insoluble particles and coats the active pharmaceutical ingredient-containing core, and a bitterness-masking layer that includes talc and at least one water-insoluble polymer, in sequence from the active pharmaceutical ingredient-containing core side; and an excipient component positioned on the outside of the fine granules, and a method for producing the same.

Abstract: A dry powder containing dry particles that contain a tiotropium salt, one or more amino acids, and acid content, and optionally, sodium chloride, and/or one or more additional therapeutic agents, wherein the molar ratio of acid to amino acid is from about 0.0005 to about 5, or 0.002 to about 1. In one aspect, the dry powder containing dry particles is suitable for administration to the respiratory tract. In one aspect, the dry powder containing dry particles is a respirable dry powder contains respirable dry particles that contain a tiotropium salt, one or more amino acids, acid content, sodium chloride, and optionally one or ore additional therapeutic agents, wherein the tiotropium salt is about 0.01% to about 0.5%, the leucine is about 5% to about 40%, the sodium chloride is about 50% to about 90%, the optional one or more additional therapeutic agents are up to about 30%, and the molar ratio of acid to amino acid is from about 0.

Abstract: The invention relates to, for example, a respirable dry powder that contains respirable dry particles that contains a tiotropium salt, one or more amino acids, sodium chloride, and optionally one or more additional therapeutic agents, where the tiotropium salt is about 0.01% to about 0.5%, the one or more amino acids is about 5% to about 40%, the sodium chloride is about 50% to about 90%, and the optional one or more additional therapeutic agents are up to about 30%, where all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%, and wherein the majority of the one or more amino acids are present in a crystalline state.

Abstract: A technique is provided for improving the stability of a halogenated isoquinoline derivative with respect to light in an aqueous composition. A pharmaceutical preparation obtained by storing an aqueous composition comprising a compound represented by Formula (1): wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, in a package that blocks a ray with a wavelength of 300 to 335 nm.

Abstract: Methods and compositions for serum-stabilizing micelles for drug delivery or imaging agent delivery are provided, as well as methods and compositions to enhance micelle-mediated drug delivery. This invention provides a process for synthesizing a lipid micelle comprising one or more lipid-oligonucleotide conjugate molecules, the process comprising contacting an amount of lipid molecules with an amount of lipid-oligonucleotide conjugate molecules sufficient to create a lipid micelle comprising lipid-oligonucleotide conjugate molecules.

Abstract: The present invention consists of a novel process for the incorporation of one or more water-soluble active agents in a hydrophilic polymer foam. Said process makes it possible in particular to obtain a hydrophilic polyurethane foam exhibiting a gradient of active agents. This process is of particular use when manufacturing hydrophilic polyurethane foams intended for medical, cosmetic and dermocosmetic purposes.

Abstract: An aerosol liposome of a marine extract and a method of producing the same are introduced. The marine extract is extracted from cell membranes of marine processing streams, including phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and lysophosphatidylcholine (LysoPC), further including at least phosphatidylserine (PS). The aerosol liposome is of a particle diameter of less than 2,000 nm. The surface of the aerosol liposome carries phosphatidylserine (PS) molecules. The aerosol liposome of a marine extract, thus provided, is simple and stable and can be absorbed through the mouth, nose, upper respiratory tract, and epidermis and engulfed by macrophages therein to quickly alleviate or regulate systematic inflammatory responses and prevent inflammation-related diseases.

Abstract: The present invention provides a pharmaceutical composition for subcutaneous administration comprising a blood factor and a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer, wherein the blood factor is not encapsulated in said colloidal particle.

Abstract: Highly bioavailable compositions and related methods of improving the bioavailability of one or more compounds are disclosed. The compositions and methods disclosed herein may be employed to improve the bioavailability of poorly soluble or poorly bioavailable ingredients (e.g., curcumin) in a subject (e.g., a mammal).

Abstract: The present invention relates to an improved active or inactive pharmaceutical ingredient-polymer composition and process of preparation thereof. In particular, the present invention relates to an improved active or inactive pharmaceutical ingredient-polymer composition and process of preparation thereof wherein the monomer encapsulates particles of active or inactive pharmaceutical ingredient at molecular level and with controlled polymerization process the monomer turns into the said polymer coat over the said active or inactive pharmaceutical ingredient that facilitates the disclosed invention to be completed a single step process.

Abstract: A process for preparing a directly compressible erythritol composition is provided that is suitable for tableting. The composition includes a binding agent such as maltodextrin.

Abstract: An emulsion-based method for the manufacture of a crystalized spherical agglomerate and/or a pharmaceutical product is provided; and crystalized spherical agglomerates and/or pharmaceutical products manufactured thereby.

Abstract: The present invention relates to a gastric-retention type sustained-release formulation of metformin as an insulin-independent diabetic agent, and a preparation method thereof. More specifically, the present invention relates to a gastric-retention type sustained-release formulation, which can effectively control drug release even with a small amount of a polymer by forming a sustained-release granulated material, which comprises granules containing metformin or a pharmaceutically acceptable salt thereof and a swellable polymer, and a water-insoluble coated on the surface of the granules; and also can allow a tablet containing the drug to swell rapidly at an early stage by formulating via mixing of a superdisintegrant, which is capable of controlling the speed of gelation forming hydrogels, with the granulated material; and a preparation method thereof.